AlloVir Analyst Ratings
AlloVir Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/18/2023 | 588.26% | B of A Securities | → $17 | Initiates Coverage On | → Buy |
| 08/07/2023 | 709.72% | Morgan Stanley | $20 → $20 | Reiterates | Overweight → Overweight |
| 04/26/2023 | 669.23% | SVB Securities | $16 → $19 | Maintains | Outperform |
| 01/27/2023 | 709.72% | Morgan Stanley | $27 → $20 | Maintains | Overweight |
| 01/23/2023 | 669.23% | SVB Leerink | $25 → $19 | Maintains | Outperform |
| 11/07/2022 | 912.15% | SVB Leerink | $24 → $25 | Maintains | Outperform |
| 09/09/2022 | 993.12% | Morgan Stanley | $32 → $27 | Maintains | Overweight |
| 07/28/2022 | 831.17% | SVB Leerink | $30 → $23 | Maintains | Outperform |
| 05/19/2022 | 1276.52% | Piper Sandler | $55 → $34 | Maintains | Overweight |
| 02/10/2022 | 1114.57% | SVB Leerink | $32 → $30 | Maintains | Outperform |
| 01/18/2022 | 1721.86% | Morgan Stanley | $48 → $45 | Maintains | Overweight |
| 12/17/2021 | 1195.55% | SVB Leerink | $37 → $32 | Maintains | Outperform |
| 11/08/2021 | 1397.98% | SVB Leerink | $41 → $37 | Maintains | Outperform |
| 10/12/2021 | 1843.32% | Morgan Stanley | $47 → $48 | Maintains | Overweight |
| 09/29/2021 | 9009.31% | Morgan Stanley | $175 → $225 | Maintains | Overweight |
| 08/18/2021 | 1802.83% | Morgan Stanley | $50 → $47 | Maintains | Overweight |
| 05/06/2021 | 1600.4% | SVB Leerink | $41 → $42 | Maintains | Outperform |
| 04/19/2021 | 1924.29% | Morgan Stanley | $49 → $50 | Maintains | Overweight |
| 08/24/2020 | 1924.29% | JP Morgan | → $50 | Initiates Coverage On | → Overweight |
| 08/24/2020 | 1883.81% | Morgan Stanley | → $49 | Initiates Coverage On | → Overweight |
| 08/24/2020 | 1559.92% | SVB Leerink | → $41 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月18日 | 588.26% | B of A证券 | →$17 | 开始承保 | →购买 |
| 08/07/2023 | 709.72% | 摩根士丹利 | $20→$20 | 重申 | 超重→超重 |
| 04/26/2023 | 669.23% | SVB证券 | $16→$19 | 维护 | 跑赢大盘 |
| 2023年1月27日 | 709.72% | 摩根士丹利 | $27→$20 | 维护 | 超重 |
| 2023年1月23日 | 669.23% | SVB Leerink | $25→$19 | 维护 | 跑赢大盘 |
| 11/07/2022 | 912.15% | SVB Leerink | $24→$25 | 维护 | 跑赢大盘 |
| 09/09/2022 | 993.12% | 摩根士丹利 | $32→$27 | 维护 | 超重 |
| 07/28/2022 | 831.17% | SVB Leerink | $30→$23 | 维护 | 跑赢大盘 |
| 2022年05月19日 | 1276.52% | 派珀·桑德勒 | $55→$34 | 维护 | 超重 |
| 02/10/2022 | 1114.57% | SVB Leerink | $32→$30 | 维护 | 跑赢大盘 |
| 01/18/2022 | 1721.86% | 摩根士丹利 | $48→$45 | 维护 | 超重 |
| 2021/12/17 | 1195.55% | SVB Leerink | $37→$32 | 维护 | 跑赢大盘 |
| 11/08/2021 | 1397.98% | SVB Leerink | $41→$37 | 维护 | 跑赢大盘 |
| 10/12/2021 | 1843.32% | 摩根士丹利 | $47→$48 | 维护 | 超重 |
| 09/29/2021 | 9009.31% | 摩根士丹利 | $175→$225 | 维护 | 超重 |
| 2021/08/18 | 1802.83% | 摩根士丹利 | $50→$47 | 维护 | 超重 |
| 05/06/2021 | 1600.4% | SVB Leerink | $41→$42 | 维护 | 跑赢大盘 |
| 04/19/2021 | 1924.29% | 摩根士丹利 | $49→$50 | 维护 | 超重 |
| 08/24/2020 | 1924.29% | 摩根大通 | →$50 | 开始承保 | →超重 |
| 08/24/2020 | 1883.81% | 摩根士丹利 | →$49 | 开始承保 | →超重 |
| 08/24/2020 | 1559.92% | SVB Leerink | →$41 | 开始承保 | →跑赢大盘 |
What is the target price for AlloVir (ALVR)?
AllVir(ALVR)的目标价是多少？
The latest price target for AlloVir (NASDAQ: ALVR) was reported by B of A Securities on August 18, 2023. The analyst firm set a price target for $17.00 expecting ALVR to rise to within 12 months (a possible 588.26% upside). 7 analyst firms have reported ratings in the last year.
A银行证券于2023年8月18日报告了allVir(纳斯达克：ALVR)的最新目标价。这家分析公司将目标价定为17美元，预计平均资产收益率将在12个月内升至(可能上涨588.26%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for AlloVir (ALVR)?
AllVir(ALVR)的最新分析师评级是多少？
The latest analyst rating for AlloVir (NASDAQ: ALVR) was provided by B of A Securities, and AlloVir initiated their buy rating.
纳斯达克(Sequoia Capital：ALVR)的最新分析师评级是由美国银行证券提供的，allVir启动了他们的买入评级。
When is the next analyst rating going to be posted or updated for AlloVir (ALVR)?
AlloVir(ALVR)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AlloVir, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AlloVir was filed on August 18, 2023 so you should expect the next rating to be made available sometime around August 18, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与阿洛维尔的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。AllVir的上一次评级是在2023年8月18日提交的，所以你应该预计下一次评级将在2024年8月18日左右提供。
Is the Analyst Rating AlloVir (ALVR) correct?
分析师对AllVir(ALVR)的评级正确吗？
While ratings are subjective and will change, the latest AlloVir (ALVR) rating was a initiated with a price target of $0.00 to $17.00. The current price AlloVir (ALVR) is trading at is $2.47, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的allVir(ALVR)评级是以0.00美元至17.00美元的目标价启动的。目前的价格为2.47美元，在分析师的预测范围内。
译文内容由第三方软件翻译。